Tags

Type your tag names separated by a space and hit enter

A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination.
Int Arch Allergy Immunol. 2007; 142(4):274-84.IA

Abstract

BACKGROUND

Allergy is an immunological disorder affecting about 25% of the population living in the industrialized countries. Specific immunotherapy is the only treatment with a long-lasting relief of allergic symptoms and able to reduce the risk of developing new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis.

METHODS

By means of DNA recombinant technology, we were able to design a head to tail dimer expressing disulphide bond variants of the major allergen of the Parietaria pollen. IgE binding activity was studied by Western blot, ELISA inhibition assays and the skin prick test. T cell recognition was studied by peripheral blood mononuclear cell proliferation. The immunogenicity of the hybrid was studied in a mouse model of sensitization.

RESULTS

In vitro and in vivo analysis showed that the disruption of specific cysteine residues in both allergens caused a strong reduction in IgE binding activity of the PjEDcys hybrid. In addition,we were able to show that a reduction in the IgE epitope content profoundly reduced the anaphylactic activity of the hybrid (from 100 to 1,000 times less than wild-type allergens) without interfering with the T cell recognition. Sera from BALB/c mice immunized with the hybrid were able to bind the natural Parietaria allergens and to inhibit the binding of human IgE to wild-type Par j 1 and Par j 2 allergens up to 90%.

CONCLUSION

Our results demonstrate that hybrid-expressing disulphide bond variants of the major allergens of the Parietaria pollen displayed reduced allergenicity and maintained T cell reactivity for induction of protective antibodies.

Authors+Show Affiliations

Istituto di Biomedicina ed Immunologia Molecolare Alberto Monroy, Consiglio Nazionale delle Ricerche, Palermo, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17124429

Citation

Bonura, A, et al. "A Hybrid Expressing Genetically Engineered Major Allergens of the Parietaria Pollen as a Tool for Specific Allergy Vaccination." International Archives of Allergy and Immunology, vol. 142, no. 4, 2007, pp. 274-84.
Bonura A, Corinti S, Artale A, et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol. 2007;142(4):274-84.
Bonura, A., Corinti, S., Artale, A., Di Felice, G., Amoroso, S., Melis, M., Geraci, D., & Colombo, P. (2007). A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. International Archives of Allergy and Immunology, 142(4), 274-84.
Bonura A, et al. A Hybrid Expressing Genetically Engineered Major Allergens of the Parietaria Pollen as a Tool for Specific Allergy Vaccination. Int Arch Allergy Immunol. 2007;142(4):274-84. PubMed PMID: 17124429.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. AU - Bonura,A, AU - Corinti,S, AU - Artale,A, AU - Di Felice,G, AU - Amoroso,S, AU - Melis,M, AU - Geraci,D, AU - Colombo,P, Y1 - 2006/11/22/ PY - 2006/02/28/received PY - 2006/07/25/accepted PY - 2006/11/25/pubmed PY - 2007/5/15/medline PY - 2006/11/25/entrez SP - 274 EP - 84 JF - International archives of allergy and immunology JO - Int Arch Allergy Immunol VL - 142 IS - 4 N2 - BACKGROUND: Allergy is an immunological disorder affecting about 25% of the population living in the industrialized countries. Specific immunotherapy is the only treatment with a long-lasting relief of allergic symptoms and able to reduce the risk of developing new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis. METHODS: By means of DNA recombinant technology, we were able to design a head to tail dimer expressing disulphide bond variants of the major allergen of the Parietaria pollen. IgE binding activity was studied by Western blot, ELISA inhibition assays and the skin prick test. T cell recognition was studied by peripheral blood mononuclear cell proliferation. The immunogenicity of the hybrid was studied in a mouse model of sensitization. RESULTS: In vitro and in vivo analysis showed that the disruption of specific cysteine residues in both allergens caused a strong reduction in IgE binding activity of the PjEDcys hybrid. In addition,we were able to show that a reduction in the IgE epitope content profoundly reduced the anaphylactic activity of the hybrid (from 100 to 1,000 times less than wild-type allergens) without interfering with the T cell recognition. Sera from BALB/c mice immunized with the hybrid were able to bind the natural Parietaria allergens and to inhibit the binding of human IgE to wild-type Par j 1 and Par j 2 allergens up to 90%. CONCLUSION: Our results demonstrate that hybrid-expressing disulphide bond variants of the major allergens of the Parietaria pollen displayed reduced allergenicity and maintained T cell reactivity for induction of protective antibodies. SN - 1018-2438 UR - https://www.unboundmedicine.com/medline/citation/17124429/A_hybrid_expressing_genetically_engineered_major_allergens_of_the_Parietaria_pollen_as_a_tool_for_specific_allergy_vaccination_ L2 - https://www.karger.com?DOI=10.1159/000097358 DB - PRIME DP - Unbound Medicine ER -